5:54 PM
 | 
Nov 08, 2013
 |  BC Extra  |  Company News

BioMarin take out speculation resurfaces

Orphan drug company BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is once again the subject of takeout rumors. According to a story in The Independent, AstraZeneca plc (LSE:AZN; NYSE:AZN) and...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >